Kite, a Gilead Company, today announced the U.S. Food and Drug Administration approved an update to the Yescarta ® prescribing information removing the previous Limitations of Use in patients with ...
Based on phase 1 safety data, the FDA has removed the Limitations of Use for Yescarta in patients with relapsed or refractory primary CNS lymphoma. The Food and Drug Administration (FDA) has approved ...
The Biosimulation and Imaging platform for new Central Nervous System drugs (BICNSD) is a 3 year project for the validation and development of a unique service based on biosimulation and imaging using ...
– Limitations of Use Removed for Rare and Aggressive Form of non-Hodgkin Lymphoma Based on Manageable Safety Profile with No New Safety Signals Identified – SANTA MONICA, Calif., February 06, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results